Navigation Links
Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation

be primarily responsible for the development of these two product candidates. Alexza has an exclusive purchase option to acquire all of the equity of Symphony Allegro at certain predetermined prices, and thereby reacquire the intellectual property rights that the Company licensed to Symphony Allegro.

About Alexza Pharmaceuticals

Alexza Pharmaceuticals is an emerging pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. The Company has four product candidates in clinical development; AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches, AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder, AZ- 004 (Staccato loxapine) for the treatment of acute agitation in patients with schizophrenia and AZ-003 (Staccato fentanyl) for the treatment of patients with acute pain.

Safe Harbor Statement

This press release includes forward-looking statements regarding the development, therapeutic potential and safety of AZ-004. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to d
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Alexza Pharmaceuticals to Present AZ-004 (Staccato Loxapine) Clinical Data at the Annual NCDEU Meeting
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:6/19/2013)... BRAINTREE, Mass. , June 19, 2013 /PRNewswire/ ... announced several important developments in the pursuit of ... (Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) , ... SANM ) for the future production of medical ... , Massachusetts. Sanmina is a leading global provider of ...
(Date:6/19/2013)... Dr. Davis Lee , CMIO for PIH Health ... 2013 AMDIS Award, a prestigious recognition saluting excellence and ... "On behalf of Allscripts, I,d like to congratulate Dr. ... efforts to improve patient care and population health," said ... Officer of Allscripts. "We are committed to our partnership ...
(Date:6/19/2013)... -- The American Association for Homecare (AAHomecare), along with a ... announced today the filing of a lawsuit in ... asking that the scheduled July 1 expansion of the Medicare ... stopped because of serious licensing irregularities. The lawsuit ... Secretary Kathleen Sebelius as the defendant. HHS oversees ...
Breaking Medicine Technology:Haemonetics Announces Next Steps in Manufacturing Transformation 2Haemonetics Announces Next Steps in Manufacturing Transformation 3Haemonetics Announces Next Steps in Manufacturing Transformation 4Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 2Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 3Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 4Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 5AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 2AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 3AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 4AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 5
... Agent Ever to Demonstrate Significant Survival Benefit ... /PRNewswire-FirstCall/ -- Bayer,HealthCare Pharmaceuticals Inc. and Onyx ... significantly,extended overall survival in patients with hepatocellular ... taking placebo by 44%,(HR=0.69; p-value=0.0006). Results were ...
... WIRE)--Jun 4, 2007 - Researchers at,Molecular Insight ... on MIP-1072, a radiolabeled, small molecule,molecular imaging ... prostate cancer at the 54th annual meeting ... Washington, D.C. MIP-1072 is,one of two development ...
Cached Medicine Technology:Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 2Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 3Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 4Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 5Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 6Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 7Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,on Molecular Imaging Pharmaceutical for Prostate Cancer 2Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,on Molecular Imaging Pharmaceutical for Prostate Cancer 3Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,on Molecular Imaging Pharmaceutical for Prostate Cancer 4
(Date:6/19/2013)... June 19, 2013 Today, Zane Benefits, ... Insurance Exchange . Zane Benefits, which provides comprehensive and ... the leader in defined contribution and ... Benefits’ website, as part of the Affordable Care Act ... will become available through new state health insurance exchanges. ...
(Date:6/19/2013)... June 19, 2013 The Journal of ... with today’s computer software, it creates questions of ethics. ... misconduct. As an already published case shows, scientific publications ... , The Journal of Parasitology features a ... in a 2004 article published in the Journal of ...
(Date:6/19/2013)... 2013) The results of three important studies have ... , official journal of the Congress of Neurological ... Lippincott Williams & Wilkins , a part of ... continuous "machine learning" using artificial neural networks (ANNs) may ... advanced brain cancers. Another study in the June ...
(Date:6/19/2013)... (June 19, 2013) In early April, senior leaders ... in Hartford, Connecticut, to discuss one question: how can ... , The preliminary results of this discussion ... Shooter Events: The Hartford Consensus ," a concept paper ... Journal of Trauma and Acute Care Surgery ...
(Date:6/19/2013)... system for repairing damage to the genetic material DNA ... may seem, those compounds are sparking optimism as potential ... mutation in BRCA, a gene that made headlines when ... compounds, termed PARP inhibitors, are the topic of the ... & Engineering News . C&EN is the weekly news ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 3Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:Hartford consensus aims to improve survival after mass shootings 2
... CA (June 18, 2010) Leading academic and professional ... online resource that will put the spotlight on research ... http://www.sagepub.com/sageinsight ) links to highly topical articles from across ... SAGE Journals Online. Drawn from both new and archive ...
... ... Pharmaceutical Business , ... York, NY (PRWEB) June 18, 2010 -- LaVoie Group, a leader in life sciences and ... Mr. Pilato will be based in New York, NY and will lead one of ...
... ... issued proceedings against Godstone farm on behalf of Todd and Aaron Furnell, twins exposed to ... ... LLP has today issued proceedings against Godstone farm on behalf of Todd and Aaron Furnell, ...
... 2010: Two separate studies have shown that vitamin D ... diseases, with over half of all patients having below the ... bodies. A further study assessing response to vitamin D ... normalise vitamin D levels in rheumatic disease patients. The results ...
... 2010: The effects of Systemic Lupus Erythematosus (SLE) may ... to results of a new study presented today at ... Against Rheumatism in Rome, Italy. In particular, the study ... Southern European subpopulations. Results from a Europe-wide study, ...
... ... Plumbing service and heating and air conditioning options for homeowners in ... have increased with the arrival of Berkey’s Plumbing, Heating and Air ... expanding its service area into Irving, Haltom City, Euless, Pantego, Hurst, ...
Cached Medicine News:Health News:LaVoie Group Adds Carey Pilato As Vice President Based In New York 2Health News:Vitamin D deficiency confirmed as common across a range of rheumatic conditions 2Health News:Vitamin D deficiency confirmed as common across a range of rheumatic conditions 3Health News:Berkey's Heating and Air Conditioning, Plumbing Service Now in Central DFW Area 2Health News:Berkey's Heating and Air Conditioning, Plumbing Service Now in Central DFW Area 3Health News:Berkey's Heating and Air Conditioning, Plumbing Service Now in Central DFW Area 4
... Independent controls for Digital Thermostat and ... clad steel. , Interiorwhite anodized aluminum ... , Oversized refrigeration (134A). , Temperature ... seal self-closing doors. , Foamed-in-place polyurethane ...
Inquire...
... The K Series CryoStorage System ... of liquid nitrogen stroage from -100C ... of solid-state automatic controls, easy accessibility ... at crogenic termperatures. On the larger ...
... refrigerators from Taylor-Wharton are uniquely designed to ... box-type storage racks and the lower operating ... The RackSystems are available in four convenient ... 750 x 2ml vials to 4800 x ...
Medicine Products: